Abstract
Strategies for the development of novel tuberculosis chemotherapeutics against existing drug resistant strains involve the identification and inhibition of novel drug targets as well as the design and synthesis of compounds against historical targets. InhA, the enoyl reductase from the mycobacterial type II fatty acid biosynthesis pathway, is a target of the frontline chemotherapeutic, isoniazid (INH). Importantly, the majority of INH-resistant clinical isolates arise from mutations in KatG, the enzyme responsible for activating isoniazid, into its active form. Thus compounds that inhibit InhA without first requiring KatG activation will be active against the majority of INH resistant strains of Mycobacterium tuberculosis. This review describes the role of InhA in cell wall biosynthesis and recent progress in the development of novel diphenyl ether-based InhA inhibitors that have activity against both sensitive and drug resistant strains of M. tuberculosis.
Keywords: InhA, enoyl reductase, fatty acid biosynthesis, mycolic acid, cell wall, mycobacterium, isoniazid, diphenyl ether, triclosan
Current Topics in Medicinal Chemistry
Title: Development of Modern InhA Inhibitors to Combat Drug Resistant Strains of Mycobacterium tuberculosis
Volume: 7 Issue: 5
Author(s): Peter J. Tonge, Caroline Kisker and Richard A. Slayden
Affiliation:
Keywords: InhA, enoyl reductase, fatty acid biosynthesis, mycolic acid, cell wall, mycobacterium, isoniazid, diphenyl ether, triclosan
Abstract: Strategies for the development of novel tuberculosis chemotherapeutics against existing drug resistant strains involve the identification and inhibition of novel drug targets as well as the design and synthesis of compounds against historical targets. InhA, the enoyl reductase from the mycobacterial type II fatty acid biosynthesis pathway, is a target of the frontline chemotherapeutic, isoniazid (INH). Importantly, the majority of INH-resistant clinical isolates arise from mutations in KatG, the enzyme responsible for activating isoniazid, into its active form. Thus compounds that inhibit InhA without first requiring KatG activation will be active against the majority of INH resistant strains of Mycobacterium tuberculosis. This review describes the role of InhA in cell wall biosynthesis and recent progress in the development of novel diphenyl ether-based InhA inhibitors that have activity against both sensitive and drug resistant strains of M. tuberculosis.
Export Options
About this article
Cite this article as:
Tonge J. Peter, Kisker Caroline and Slayden A. Richard, Development of Modern InhA Inhibitors to Combat Drug Resistant Strains of Mycobacterium tuberculosis, Current Topics in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/156802607780059781
DOI https://dx.doi.org/10.2174/156802607780059781 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Meet Our Editorial Board Member:
Current Computer-Aided Drug Design Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Is the Deficiency of Vitamin B12 Related to Oxidative Stress and Neurotoxicity in Parkinsons Patients?
CNS & Neurological Disorders - Drug Targets HIV Genetic Diversity: Biological and Public Health Consequences
Current HIV Research Plombage: A Forgotten Surgical Treatment for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Exploration of Ion Channels in Mycobacterium tuberculosis: Implication on Drug Discovery and Potent Drug Targets Against Tuberculosis
Current Chemical Biology Combinatorial Design of Molecule using Activity-Linked Substructural Topological Information as Applied to Antitubercular Compounds
Current Computer-Aided Drug Design Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction of the Aging Innate Immune System
Current Immunology Reviews (Discontinued) Application of Computational Techniques to Unravel Structure-Function Relationship and their Role in Therapeutic Development
Current Topics in Medicinal Chemistry Lessons from Seven Decades of Antituberculosis Drug Discovery
Current Topics in Medicinal Chemistry Oligonucleotide Profiling for Discriminating Bacteria in Bacterial Communities
Combinatorial Chemistry & High Throughput Screening Micelle-based Systems for Pulmonary Drug Delivery and Targeting
Drug Delivery Letters Protein Kinase Inhibitors as Potential Antimicrobial Drugs Against Tuberculosis, Malaria and HIV
Current Pharmaceutical Design Centrality Measures in Biological Networks
Current Bioinformatics Effect of Contrast-enhanced Contemporaneous <sup>18</sup>F-FDG PET/CT on Semi Quantification Uptake Value Using Third Party Viewing Workstation
Recent Patents on Medical Imaging Factors Affecting Sexual Transmission of HIV-1: Current Evidence and Implications for Prevention
Current HIV Research Applications and Case Studies of the Next-Generation Sequencing Technologies in Food, Nutrition and Agriculture
Recent Patents on Food, Nutrition & Agriculture Immunity to Tuberculosis and Novel Therapeutic Strategies
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Gold - Old Drug with New Potentials
Current Medicinal Chemistry